Patents Assigned to AstraZeneca AB
  • Patent number: 11352369
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 7, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Patent number: 11325906
    Abstract: The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: May 10, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Jeffrey Wallace Johannes, Sudhir Mahadeo Hande, Sebastien Louis Degorce, Martin John Packer
  • Patent number: 11311558
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: April 26, 2022
    Assignee: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Patent number: 11254928
    Abstract: Provided herein, in some embodiments, are nucleic acid-based tools that may be used for high-throughput functional genomics studies as well as for the generation of knockout (gene inactivation or deletion) or knockin (gene activation or insertion) cell lines. Tools of the present disclosure include an “activatable reporter cassette,” a guide RNA construct and a nuclease that can be used together, for example, to modify and isolate targeted cells of interest.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 22, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Marcello Maresca, Amir Taheri-Ghahfarokhi, Mohammad Bohlooly-Yeganeh, Lorenz M. Mayr
  • Patent number: 11248001
    Abstract: The invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: February 15, 2022
    Assignee: AstraZeneca AB
    Inventors: Michael H. Serrano-Wu, Mark Chambers, Erica Goldsmith, Jason Tierney, Karamjit Jandu, David Clark, Paul Hinchliffe
  • Patent number: 11236095
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: February 1, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • Patent number: 11180477
    Abstract: An improved chemical process for the manufacture of the compound of Formula (I), which is useful, for example, as a late-stage chemical intermediate in the production of osimertinib (AZD9291) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: November 23, 2021
    Assignee: AstraZeneca AB
    Inventors: Alistair John Boyd, Alexander Telford
  • Publication number: 20210355127
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: April 22, 2021
    Publication date: November 18, 2021
    Applicant: ASTRAZENECA AB
    Inventors: Johan Olof Broddefalk, Hans Fredrik Emtenäs, Kenneth Lars Granberg, Malin Anita Lemurell, Daniel Tor Pettersen, Alleyn Thomas Plowright, Lars Johan Andreas Ulander
  • Publication number: 20210322415
    Abstract: Methods comprising repeating cycles of administration of a composition comprising cediranib according to a fixed intermittent dosing regimen comprising administration of an effective amount of the composition comprising cediranib on one or more consecutive days of a cycle followed by one or more consecutive days of rest on which said composition is not administered are disclosed herein, and may be used as monotherapy or may comprise administration of one or more partner drugs or therapies and may be used in combination therapy.
    Type: Application
    Filed: February 14, 2017
    Publication date: October 21, 2021
    Applicants: ASTRAZENECA AB, THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Simon BARRY, Jane KENDREW, Tony HO, Stephen Robert WEDGE, Susan Percy IVY, Elise KOHN, Jung-Min LEE
  • Patent number: 11149029
    Abstract: The present disclosure relates to salts of compounds of Formula (I) prepared as a xinafoate (1-hydroxy-2-naphthoate) salt (Formula (Ia)), pharmaceutically acceptable compositions comprising same and methods of using the same.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: October 19, 2021
    Assignee: AstraZeneca AB
    Inventors: Anna Matilda Angelica Pettersen, James McCabe, Carl-Johan Aurell
  • Patent number: 11149024
    Abstract: Disclosed are intermediates and methods of synthesizing Compound 1.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 19, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Craig Robert Stewart, Simon Hardy, Andrew Stark, Alexander Hird, Qing Ye, Xiaolan Zheng, Cati Ferrar, Jan Koek, Debasis Hazra
  • Patent number: 11136340
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 5, 2021
    Assignee: AstraZeneca AB
    Inventors: Maurice Raymond Verschoyle Finlay, Frederick Woolf Goldberg, Attilla Kuan Tsuei Ting
  • Patent number: 11117874
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: September 14, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Staffan PO Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Publication number: 20210230184
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 29, 2021
    Applicant: AstraZeneca AB
    Inventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, XiaoLan ZHENG
  • Patent number: 11053223
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation, pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: July 6, 2021
    Assignee: AstraZeneca AB
    Inventors: Tudor Grecu, Jason Grant Kettle, Martin John Packer, Stuart Eric Pearson, James Michael Smith
  • Patent number: 11046689
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: June 29, 2021
    Assignee: AstraZeneca AB
    Inventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
  • Patent number: 11034654
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: June 15, 2021
    Assignee: AstraZeneca AB
    Inventors: Sarah Lever, Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg
  • Patent number: 11000525
    Abstract: There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 11, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Tord Bertil Inghardt, Petra Johannesson, Ulrik Jurva, Erik Michaelsson, Eva-Lotte Lindstedt-Alstermark, Nicholas Tomkinson, Jeffrey Paul Stonehouse, Li-Ming Gan
  • Patent number: 11001589
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: May 11, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Johan Olof Broddefalk, Hans Fredrik Emtenâs, Kenneth Lars Granberg, Malin Anita Lemurell, Daniel Tor Pettersen, Alleyn Thomas Plowright, Lars Johan Andreas Ulander
  • Publication number: 20210130901
    Abstract: Biomarkers for the treatment of pathological conditions associated with the PI3K pathway, such as cancer, and methods of using inhibitors of upstream components of the PI3K pathway, such as PI3K-? inhibitors or AKT inhibitors, are described. In particular, there are described biomarkers for patient selection in the treatment of cancer, as well as methods of therapeutic treatment, diagnostic kits and methods of detection, wherein cancers that possess a mutation in an upstream component of the PI3K pathway (such as the PIK3CA gene and/or the AKT gene), and a wild-type MAP3K1 gene and MAP2K4 gene, are more likely to respond favourably to treatment with inhibitors of upstream components of the PI3K pathway.
    Type: Application
    Filed: September 16, 2016
    Publication date: May 6, 2021
    Applicant: ASTRAZENECA AB
    Inventors: Alvaro AVIVAR VALDERAS, Francisco Humberto CRUZALEGUI, Kevin HUDSON, Robert Kenneth McEWEN